Mandate

Vinge advises Nexstim on its dual listing on First North Finland and First North Sweden

November 14, 2014

Vinge advised Nexstim on its IPO and dual listing of shares on First North Finland and First North Sweden. In the IPO, Nexstim issued 2,408,339 news shares at a subscription price of EUR 6.35 per share, amounting to gross proceeds of roughly EUR 15.3 million. Trading in the company's shares on First North Finland and First North Sweden commenced on 14 November 2014. The transaction is the first ever dual listing on the First North exchanges maintained by Nasdaq.

Nexstim is a medical technology company based in Finland that aims to improve rehabilitation for stroke patients. 

Vinge’s team primarily consisted of Jesper Schönbeck, Joakim Hagberg, Tora Hansjons and Nils Fredrik Dehlin.

Related

Vinge advises Cantargia in connection with the sale of immunology program CAN10

Vinge advises Cantargia AB (publ) in connection with the sale of its early-clinical stage IL1RAP immunology program CAN10 to the Japanese healthcare company Otsuka Pharmaceutical.
July 21, 2025

Vinge has assisted PulPac in connection with it obtaining a €20 million financing from the European Investment Bank

Vinge has assisted Gothenburg-based sustainable packaging technology company PulPac in connection with it obtaining a €20 million (around 220 million Swedish kronor) financing from the European Investment Bank (EIB).
July 18, 2025

Vinge has advised Behold Ventures in the fundraising of Behold Ventures’ first-time fund

Behold Ventures held its final closing on 27 June 2025, thereby securing investor commitments to its first-time fund amounting to approximately SEK 550 million from an international investor base, comprising the European Investment Fund (EIF), among others.
July 10, 2025